| __timestamp | Teva Pharmaceutical Industries Limited | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 9216000000 | 17293000 |
| Thursday, January 1, 2015 | 8296000000 | 26470000 |
| Friday, January 1, 2016 | 10044000000 | 28307000 |
| Sunday, January 1, 2017 | 11560000000 | 30354000 |
| Monday, January 1, 2018 | 10558000000 | 32160000 |
| Tuesday, January 1, 2019 | 9351000000 | 37571000 |
| Wednesday, January 1, 2020 | 8933000000 | 39951000 |
| Friday, January 1, 2021 | 8284000000 | 50159000 |
| Saturday, January 1, 2022 | 7952000000 | 54577000 |
| Sunday, January 1, 2023 | 8200000000 | 61940000 |
| Monday, January 1, 2024 | 8480000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial. Over the past decade, Teva Pharmaceutical Industries Limited and Vericel Corporation have showcased distinct financial trajectories. Teva, a global leader, saw its cost of revenue peak in 2017, reaching approximately 11.56 billion, before experiencing a gradual decline to around 8.2 billion by 2023. This represents a 29% decrease, reflecting strategic shifts and market challenges.
Conversely, Vericel, a smaller yet dynamic player, demonstrated consistent growth. From 2014 to 2023, its cost of revenue surged by over 250%, from 17.3 million to 61.9 million. This growth underscores Vericel's expanding market presence and operational scaling.
These insights highlight the contrasting paths of two pharmaceutical entities, offering a window into their strategic priorities and market responses over the years.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Teva Pharmaceutical Industries Limited
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Vericel Corporation
Cost Insights: Breaking Down Zoetis Inc. and Vericel Corporation's Expenses
Cost of Revenue Trends: Teva Pharmaceutical Industries Limited vs Pharming Group N.V.
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and Lantheus Holdings, Inc.
Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Veracyte, Inc.
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: PTC Therapeutics, Inc. vs Vericel Corporation
Comparing Cost of Revenue Efficiency: Vericel Corporation vs Supernus Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Vericel Corporation and Taro Pharmaceutical Industries Ltd.
Cost Insights: Breaking Down Vericel Corporation and Evotec SE's Expenses
Cost Insights: Breaking Down Vericel Corporation and MiMedx Group, Inc.'s Expenses